BioCentury
ARTICLE | Company News

PhaseBio, Duke University deal

April 4, 2016 7:00 AM UTC

PhaseBio granted the university exclusive rights to conjugate small molecule oncologic ( SMO) drugs to PhaseBio’s Elastin-Like Polypeptide (ELP) technology. The resulting compounds are known as High T...